Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.43 |
| ▸ | FABP7 | O15540 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | MDM4 | O15151 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1000230 | 1.00 | KMT2A (0.44) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL30023067 | 0.84 | KMT2A (0.44) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL30022935 | 0.84 | KMT2A (0.44) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL30023266 | 0.84 | KMT2A (0.44) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL1000148 | 0.84 | KMT2A (0.48) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL29468874 | 0.84 | KMT2A (0.48) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL1000147 | 0.84 | KMT2A (0.48) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL7127095 | 0.84 | KMT2A (0.43) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL28936568 | 0.83 | KMT2A (0.41) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL27605680 | 0.83 | KMT2A (0.43) | KMT2AFABP5FABP7CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6660832-B1 | Cyclic peptide compounds with fused benzene rings; solid phase synthesis thereof; use as antibiotic to treat bacterial infection in mammals; may work by binding to RNA targets | ISIS PHARMACEUTICALS, INC. | 2003-12-09 | — | — | US | disclosed |